Scarica l'app Stockscreener
4.89
0.10%
0.005
Precedente Chiudi:
$4.885
Aprire:
$5.1
Volume 24 ore:
58,476
Relative Volume:
0.03
Capitalizzazione di mercato:
$9.90M
Reddito:
-
Utile/perdita netta:
$-5.73M
Rapporto P/E:
-0.7466
EPS:
-6.55
Flusso di cassa netto:
$-4.13M
1 W Prestazione:
-5.60%
1M Prestazione:
+8.19%
6M Prestazione:
+106.33%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.7101
$5.16
Intervallo di 1 settimana:
$4.7101
$5.665
Portata 52W:
$1.62
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Nome
Dogwood Therapeutics Inc
Settore
Industria
Telefono
(866) 620-8655
Indirizzo
44 MILTON AVENUE, ALPHARETTA
Confronta DWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
4.89 | 9.90M | 0 | -5.73M | -4.13M | -6.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Dogwood Therapeutics Inc Borsa (DWTX) Ultime notizie
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference - GlobeNewswire
Emerging Biotech Dogwood Therapeutics Reveals Growth Strategy at Sidoti Small-Cap Conference - Stock Titan
Dogwood (DWTX) Pursues $150M Mixed Securities Offering | DWTX St - GuruFocus
DWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway… - Yahoo Finance
DWTX: Dogwood Therapeutics Expands Research on Pain Management | - GuruFocus
Dogwood Therapeutics Reports Progress in Pain Treatment Trials - TipRanks
Dogwood Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Dogwood Therapeutics Announces First Quarter 2025 Financial Results - The Manila Times
Dogwood Therapeutics Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView
Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Exclusive Access: Dogwood Therapeutics CEO Hosts Private Investor Meetings at Prestigious NYC Conference - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Upgraded at HC Wainwright - Defense World
HC Wainwright & Co. Upgrades Dogwood Therapeutics (DWTX) - Nasdaq
HC Wainwright Upgrades Dogwood Therapeutics to Buy From Neutral - marketscreener.com
Financial Metrics Unveiled: Dogwood Therapeutics Inc (DWTX)’s Key Ratios in the Spotlight - DWinneX
H.C. Wainwright lifts Dogwood stock rating, doubles price target - Investing.com
Best Biotech Stocks To Watch Today – April 21st - Defense World
Dogwood Therapeutics Inc (NASDAQ: DWTX) Has Been Trading Down. What Are The Prospects For The Future? - Stocksregister
You might want to take a look at Dogwood Therapeutics Inc (DWTX) now - Sete News
You Should Read This Analysis Before Investing in Dogwood Therapeutics Inc (NASDAQ:DWTX) - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Dogwood Therapeutics (DWTX) Begins Phase 2b Trial for Halneuron - GuruFocus
Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance - GuruFocus
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance with Equit - GuruFocus
Dogwood Therapeutics regains Nasdaq compliance By Investing.com - Investing.com South Africa
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance - marketscreener.com
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewswire
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Sodium Channel Blockers Clinical Trial Pipeline Accelerates - GlobeNewswire
DWTX: Interim Data for Phase 2b Trial in 4Q25… - Yahoo Finance
Dogwood Therapeutics regains compliance with Nasdaq - MSN
DWTX: Interim Data for Phase 2b Trial in 4Q25 - Research Tree
Dogwood Therapeutics Announces Nasdaq Compliance Regained - Nasdaq
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Dogwood Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Dogwood Therapeutics, Inc. SEC 10-K Report - TradingView
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Dogwood Strengthens Balance Sheet with $24M Capital Actions as Halneuron Trial Progresses - Stock Titan
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain By Investing.com - Investing.com South Africa
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet… - Zacks Small Cap Research
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain - Marketscreener.com
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain - Investing.com
Dogwood Therapeutics Announces Dosing of First Patient in - GlobeNewswire
Revolutionary Non-Addictive Pain Treatment Enters Critical Phase 2b Trial for Cancer Patients - StockTitan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Dogwood Therapeutics Inc Azioni (DWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):